Edward J. Olhava

8.5k total citations · 2 hit papers
27 papers, 3.8k citations indexed

About

Edward J. Olhava is a scholar working on Molecular Biology, Hematology and Organic Chemistry. According to data from OpenAlex, Edward J. Olhava has authored 27 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 12 papers in Hematology and 8 papers in Organic Chemistry. Recurrent topics in Edward J. Olhava's work include Epigenetics and DNA Methylation (14 papers), Acute Myeloid Leukemia Research (12 papers) and Cancer-related gene regulation (11 papers). Edward J. Olhava is often cited by papers focused on Epigenetics and DNA Methylation (14 papers), Acute Myeloid Leukemia Research (12 papers) and Cancer-related gene regulation (11 papers). Edward J. Olhava collaborates with scholars based in United States, United Kingdom and Tunisia. Edward J. Olhava's co-authors include William Roush, H. Martin Seidel, Eicke Latz, Gary D. Glick, Matthew Mangan, David A. Evans, Jeffrey S. Johnson, Robert A. Copeland, Margaret Porter Scott and Roy M. Pollock and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Blood.

In The Last Decade

Edward J. Olhava

27 papers receiving 3.7k citations

Hit Papers

Targeting the NLRP3 inflammasome in inflammatory dise... 2013 2026 2017 2021 2018 2013 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting the NLRP3 inflammasome in inflammatory diseases
    2018 1.5k citations Matthew Mangan, Edward J. Olhava et al. Nature Reviews Drug Discovery profile →
  2. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
    2013 546 citations Scott R. Daigle, Edward J. Olhava et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edward J. Olhava United States 19 2.7k 626 601 492 244 27 3.8k
Colin Reily United States 17 1.7k 0.7× 616 1.0× 349 0.6× 180 0.4× 149 0.6× 29 2.8k
H. Martin Seidel United States 23 2.0k 0.8× 1.1k 1.7× 190 0.3× 184 0.4× 762 3.1× 37 3.3k
Weixiong Zhong United States 41 2.3k 0.9× 548 0.9× 217 0.4× 92 0.2× 545 2.2× 117 4.7k
Daniela Rossi Italy 30 1.2k 0.4× 253 0.4× 388 0.6× 134 0.3× 91 0.4× 147 2.8k
Lise Binderup Denmark 40 1.8k 0.7× 602 1.0× 230 0.4× 162 0.3× 1.2k 5.0× 138 5.1k
Robert A. Orlando United States 38 1.7k 0.6× 465 0.7× 92 0.2× 261 0.5× 353 1.4× 80 4.1k
J. Fred Nagelkerke Netherlands 32 1.4k 0.5× 538 0.9× 154 0.3× 111 0.2× 647 2.7× 87 3.6k
Paul Foster United Kingdom 34 1.0k 0.4× 325 0.5× 374 0.6× 806 1.6× 307 1.3× 101 3.3k
Cécile Mazière France 31 1.2k 0.4× 441 0.7× 232 0.4× 69 0.1× 241 1.0× 119 2.9k
Alakananda Basu United States 36 3.3k 1.2× 305 0.5× 386 0.6× 177 0.4× 1.4k 5.7× 109 5.1k

Countries citing papers authored by Edward J. Olhava

Since Specialization
Citations

This map shows the geographic impact of Edward J. Olhava's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward J. Olhava with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward J. Olhava more than expected).

Fields of papers citing papers by Edward J. Olhava

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward J. Olhava. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward J. Olhava. The network helps show where Edward J. Olhava may publish in the future.

Co-authorship network of co-authors of Edward J. Olhava

This figure shows the co-authorship network connecting the top 25 collaborators of Edward J. Olhava. A scholar is included among the top collaborators of Edward J. Olhava based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward J. Olhava. Edward J. Olhava is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mangan, Matthew, Edward J. Olhava, William Roush, et al.. (2018). Erratum: Targeting the NLRP3 inflammasome in inflammatory diseases. Nature Reviews Drug Discovery. 17(9). 688–688. 349 indexed citations
2.
Mangan, Matthew, Edward J. Olhava, William Roush, et al.. (2018). Targeting the NLRP3 inflammasome in inflammatory diseases. Nature Reviews Drug Discovery. 17(8). 588–606. 1460 indexed citations breakdown →
3.
Campbell, Carly, David A. Drubin, Timothy M. Thomson, et al.. (2017). Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged Leukemia. Molecular Cancer Therapeutics. 16(8). 1669–1679. 46 indexed citations
4.
Waters, Nigel J., Sherri Smith, Edward J. Olhava, et al.. (2015). Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human. Cancer Chemotherapy and Pharmacology. 77(1). 43–62. 23 indexed citations
5.
Waters, Nigel J., Scott R. Daigle, Aravind Basavapathruni, et al.. (2015). Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target. Journal of Controlled Release. 220(Pt B). 758–765. 21 indexed citations
6.
Daigle, Scott R., Carly Campbell, Nigel J. Waters, et al.. (2015). Abstract 2701: Characterization of acquired EPZ-5676 resistance in cell line models of MLL rearranged leukemia. Cancer Research. 75(15_Supplement). 2701–2701. 1 indexed citations
7.
Klaus, Christine R., Danielle Johnston, J. Joshua Smith, et al.. (2014). DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells. Journal of Pharmacology and Experimental Therapeutics. 350(3). 646–656. 96 indexed citations
8.
Basavapathruni, Aravind, Edward J. Olhava, Scott R. Daigle, et al.. (2014). Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor. Biopharmaceutics & Drug Disposition. 35(4). 237–252. 64 indexed citations
9.
Daigle, Scott R., Edward J. Olhava, Aravind Basavapathruni, et al.. (2013). Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 122(6). 1017–1025. 546 indexed citations breakdown →
10.
Deshpande, Aniruddha J., Liying Chen, Maurizio Fazio, et al.. (2013). Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 121(13). 2533–2541. 131 indexed citations
11.
Basavapathruni, Aravind, Lei Jin, Scott R. Daigle, et al.. (2012). Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L. Chemical Biology & Drug Design. 80(6). 971–980. 114 indexed citations
12.
Chen, Liang, Anagha Deshpande, Deepti Banka, et al.. (2012). Abrogation of MLL–AF10 and CALM–AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 27(4). 813–822. 101 indexed citations
13.
Copeland, Robert A., Edward J. Olhava, & Margaret Porter Scott. (2010). Targeting epigenetic enzymes for drug discovery. Current Opinion in Chemical Biology. 14(4). 505–510. 87 indexed citations
14.
Blackburn, Christopher, Kenneth M. Gigstad, Paul Hales, et al.. (2010). Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit. Biochemical Journal. 430(3). 461–476. 129 indexed citations
15.
Evans, David A., Lisbet Kværnø, Jason A. Mulder, et al.. (2007). Total Synthesis of (+)‐Azaspiracid‐1. Part I: Synthesis of the Fully Elaborated ABCD Aldehyde. Angewandte Chemie International Edition. 46(25). 4693–4697. 34 indexed citations
16.
Evans, David A., Lisbet Kværnø, Jason A. Mulder, et al.. (2007). Total Synthesis of (+)‐Azaspiracid‐1. Part I: Synthesis of the Fully Elaborated ABCD Aldehyde. Angewandte Chemie. 119(25). 4777–4781. 10 indexed citations
17.
Evans, David A., Travis B. Dunn, Lisbet Kværnø, et al.. (2007). Total Synthesis of (+)‐Azaspiracid‐1. Part II: Synthesis of the EFGHI Sulfone and Completion of the Synthesis. Angewandte Chemie International Edition. 46(25). 4698–4703. 44 indexed citations
18.
Evans, David A., Jeffrey S. Johnson, & Edward J. Olhava. (2000). Enantioselective Synthesis of Dihydropyrans. Catalysis of Hetero Diels−Alder Reactions by Bis(oxazoline) Copper(II) Complexes. Journal of the American Chemical Society. 122(8). 1635–1649. 260 indexed citations
19.
Evans, David A., Edward J. Olhava, Jeffrey S. Johnson, & Jacob M. Janey. (1998). ChiraleC2-symmetrische CuII-Komplexe als Katalysatoren für enantioselektive Hetero-Diels-Alder-Reaktionen. Angewandte Chemie. 110(24). 3553–3557. 26 indexed citations
20.
Evans, David A., Edward J. Olhava, Jeffrey S. Johnson, & Jacob M. Janey. (1998). ChiralC2-Symmetric CuII Complexes as Catalysts for Enantioselective Hetero-Diels-Alder Reactions. Angewandte Chemie International Edition. 37(24). 3372–3375. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Colin Reily Breakdown of academic impact, for papers by H. Martin Seidel Breakdown of academic impact, for papers by Weixiong Zhong Breakdown of academic impact, for papers by Daniela Rossi Breakdown of academic impact, for papers by Lise Binderup Breakdown of academic impact, for papers by Robert A. Orlando Breakdown of academic impact, for papers by J. Fred Nagelkerke Breakdown of academic impact, for papers by Paul Foster Breakdown of academic impact, for papers by Cécile Mazière Breakdown of academic impact, for papers by Alakananda Basu
Rankless by CCL
2026